Erasca (ERAS) vs Veradermics (MANE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Veradermics is the larger company by market cap ($5.25 billion vs $4.97 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ERAS | MANE |
|---|---|---|
| Share price | $14.20 | $125.54 |
| Market cap | $4.97B | $5.25B |
| 1-day change | +0.57% | +13.15% |
| YTD return | +279.57% | — |
| 1-year return | +469.35% | — |
| 5-year return | -20.67% | — |
| EPS (TTM) | $-0.95 | $-4.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-124.55M | $-70.00M |
| 52-week high | $24.28 | $136.72 |
| 52-week low | $2.11 | $32.00 |
| Distance from 52-week high | -41.52% | -8.17% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +69.79% | +30.24% |
| Average volume | 4.28M | 729.81K |
| Shares outstanding | 349.76M | 41.78M |
| Employees | 103 | 37 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Erasca
ERAS stock →Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
About Veradermics
MANE stock →Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
ERAS vs MANE FAQ
Which is bigger, Erasca or Veradermics?
Veradermics (MANE) is larger, with a market capitalization of $5.25B compared with $4.97B for Erasca (ERAS).
Are Erasca and Veradermics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.